Mitochondrial targeted doxorubicin derivatives delivered by ROS-responsive nanocarriers to breast tumor for

Xin-Cheng Zhong1, Ming-Han Shi2, Hui-Na Liu1

  • 1Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, People's Republic of China.

Insights

This study developed novel nanocarriers to overcome multidrug resistance in breast cancer. These targeted nanoparticles deliver doxorubicin effectively, enhancing antitumor activity and providing a promising chemotherapy strategy.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Oncology

Background:

  • Multidrug resistance (MDR) significantly challenges chemotherapy efficacy, particularly in breast cancer treatment.
  • Mitochondria play a crucial role in MDR by providing energy for drug efflux.
  • Targeting mitochondria with drugs like doxorubicin offers a strategy to overcome MDR.

Purpose of the Study:

  • To develop novel ROS-responsive and CD44-targeting nanocarriers for enhanced doxorubicin delivery.
  • To investigate the potential of these nanocarriers in overcoming MDR in breast cancer.

Main Methods:

  • Synthesis of mitochondria-targeted doxorubicin (TPP-DOX) and ROS-responsive hyaluronic acid derivatives (HA-PBPE).
  • Characterization of nanocarriers (TPP-DOX@HA-PBPE) with a particle size of approximately 200 nm.
  • Evaluation of in vitro antitumor activity and in vivo tumor passive targeting.

Main Results:

  • Successfully synthesized and characterized TPP-DOX and HA-PBPE, forming stable TPP-DOX@HA-PBPE nanocarriers.
  • Demonstrated enhanced in vitro antitumor activity compared to free doxorubicin.
  • Showcased improved tumor passive targeting in vivo.

Conclusions:

  • The developed ROS-responsive TPP-DOX@HA-PBPE nanocarrier system shows promise for reversing MDR.
  • This strategy facilitates efficient delivery of doxorubicin derivatives into drug-resistant cancer cells.
  • Offers a novel approach for overcoming chemotherapy resistance in breast cancer.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.3K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
17.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K